background
Logo
Quintessence Biosciences, Inc.
505 South Rosa Road
Madison, Wisconsin 53719 USA
Phone: +1-608.441.2950
Fax: +1-608.441.2952
background
Main Image

 

EVade™ RNase QBI-139

Development Status

For information about the science behind the creation of EVade™ RNase QBI-139 click here.

In Spetember 2006, QBI-139 was selected as the lead candidate. Large scale production began in early 2007, and toxicology studies have been completed. The Company is on target to submit an Investigational New Drug Application in the first half of 2008, which would allow a Phase 1 clinical trial to begin soon after.

In selecting the lead candidate, over thirty EVade™ RNases were manufactured and tested in vivo against a variety of cancers. QBI-139 was selected because of its broad efficacy and excellent safety profile. QBI-139 causes significant tumor growth inhibition in pancreatic, prostate, non-small cell lung, and ovarian cancers.

 
© 2008 Quintessence Biosciences, Inc. .
Home | About Us | Product Pipeline | Technology | News | Contact | Search